In addition, the pathological mechanisms that are associated with C9orf72 variants only cover a fraction of ALS patients’ causes; solely targeting C9orf72 variants and their downstream targets could not benefit all ALS patients. This evidence concerns the gene C9orf72 and amyotrophic lateral sclerosis.